Cullinan Therapeutics, Inc. CGEM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $188.07M+22.3% | $187.4M+31.1% | $184.95M+34.7% | $178.49M+31.7% | $153.72M+21.3% | ||
| $52.28M-5.3% | $54.25M+0.4% | $56.49M+12.8% | $56.21M+17.8% | $55.21M+25.0% | ||
| $240.35M+15.0% | $241.65M+22.7% | $241.44M+28.9% | $234.7M+28.0% | $208.93M+22.3% | ||
| -$240.35M-15.0% | -$241.65M-22.7% | -$241.44M-28.9% | -$234.7M-27.7% | -$208.93M-21.9% | ||
| -$420K-70.7% | -$443K-116% | -$374K— | -$355K— | -$246K— | ||
| -$221.04M-23.7% | -$219.88M-31.4% | -$216.81M-51.0% | -$206.76M-45.4% | -$178.74M-35.1% | ||
| —— | —— | —— | —— | —— | ||
| -$240.04M-15.1% | -$241.34M-22.7% | -$241.13M-28.9% | -$234.39M-27.8% | -$208.62M-22.0% | ||
| -$240.35M-15.0% | -$241.65M-22.7% | -$241.44M-28.9% | -$234.7M-27.7% | -$208.93M-21.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Cullinan Therapeutics, Inc. profitable?
- Cullinan Therapeutics, Inc. is not currently profitable: it reported a net loss of $221.0M over the trailing twelve months, a -346.1% net margin.
- What is Cullinan Therapeutics, Inc.'s earnings per share?
- Cullinan Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.84.
- Where does Cullinan Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.